retatrutide fda approval timeline Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and Retatrutide vs CagriSema: The Battle

Using tools like the peptide stack calculator and reconstitution calculator helps ensure accurate dosing, which directly affects the intensity of gastric emptying and therefore sulfur burp severity

Why Target GIP

In ATTAIN-1, adverse event-related discontinuation rates were 5.3% with orforglipron 6 mg, 7.6% with 12 mg, and 10.3% with 36 mg, compared with 2.7% with placebo

Although the study was not powered to assess cognitive changes, researchers found that patients who received liraglutide had an 18% slower decline in cognitive function in a year compared to those who got the placebo

Due to the ability to ameliorate IR and lipotoxicity in the pathogenesis of NASH, GLP-1R is a potential therapeutic target for NASH